Neurophth Biotechnology Ltd., a fully integrated genomic medicines company seeking to improve lives through the curative potential of gene therapies, announced the opening of its state-of-the-art manufacturing facility at the Phase II Suzhou Biomedical Industrial Park (BioBAY) in Suzhou, China.

The 8,000 square-meter gene therapy-focused current good manufacturing practice (cGMP) production facility includes two drug substance production suites, two filling lines, a cell banking suite, a technology transfer laboratory and a quality-control laboratory. Neurophth's proprietary manufacturing processes will take advantage of single-use equipment to aid in quick and effective product changeovers and equipment cleaning. The Suzhou facility has already employed over 100 employees.

"Neurophth's own cGMP production facility is designed to enable us to reach manufacturing scales suitable for future commercial production and the facility is also co-located with our development laboratories," said Bin Li, Chairman and Founder at Neurophth. "This integrated approach allows for more efficient development, manufacturing and release of vectors for new indications and we will continue to adhere to the patient-centric innovation and contribute to the development of Suzhou BioBAY."